Clorox Company (CLX) Slips -1.4% on Higher than Average Trading Volume

Large-cap Consumer Discretionary company Clorox Company has moved -1.4% so far today on a volume of 865,693, compared to its average of 1,191,163. In contrast, the S&P 500 index moved 0.0%.

Clorox Company trades 0.48% away from its average analyst target price of $153.55 per share. The 17 analysts following the stock have set target prices ranging from $124.0 to $185.0, and on average have given Clorox Company a rating of hold.

If you are considering an investment in CLX, you'll want to know the following:

  • Clorox Company's current price is 9786.4% above its Graham number of $1.56, which implies that at its current valuation it does not offer a margin of safety

  • Based on its trailing earnings per share of 0.6, Clorox Company has a trailing 12 month Price to Earnings (P/E) ratio of 257.1 while the S&P 500 average is 15.97

  • CLX has a forward P/E ratio of 27.1 based on its forward 12 month price to earnings (EPS) of $5.69 per share

  • The company has a price to earnings growth (PEG) ratio of 2.48 — a number near or below 1 signifying that Clorox Company is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 6428.54 compared to its sector average of 3.12

  • The Clorox Company manufactures and markets consumer and professional products worldwide.

  • Based in Oakland, the company has 9,000 full time employees and a market cap of $19.07 Billion. Clorox Company currently returns an annual dividend yield of 3.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.